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AbstrAct
Liver transplantation is a highly successful 
treatment for all types of liver failure, some 
non- liver failure indications and liver cancer. 
Most referrals come from secondary care. 
This first part of a two- part guideline outlines 
who to refer, and how that referral should be 
made, including patient details and additional 
issues such as those relevant to alcohol and 
drug misuse. The process of liver transplant 
assessment involves the confirmation of the 
diagnosis and non- reversibility, an evaluation of 
comorbidities and exclusion of contraindications. 
Finally, those making it onto the waiting list 
require monitoring and optimising. Underpinning 
this process is a need for good communication 
between patient, their carers, secondary care and 
the liver transplant service, synchronised by the 
transplant coordinator. Managing expectation 
and balancing the uncertainty of organ 
availability against the inevitable progression of 
underlying liver disease requires sensitivity and 
honesty from all healthcare providers and the 
assessment of palliative care needs is an integral 
part of this process.
IntroductIon
Over just three decades, UK liver trans-
plantation has evolved from the enthu-
siastic efforts of a few well- intentioned 
clinicians to a multidisciplinary, closely 
scrutinised therapy with 1- year survival 
rates in excess of 90%.1–3 Despite these 
excellent outcomes, only a small fraction 
of the increasing numbers of patients 
dying of end- stage liver disease will be 
referred to a liver transplant unit (LTU) 
for this life- saving procedure.
This two- part guideline is specifically 
aimed at non- specialist clinicians caring 
for patients with acute and chronic liver 
disease (CLD). The first part examines:
 ► Who to refer for liver transplant (LT).
 ► How to refer for LT.
 ► The LT Assessment.
 ► How to manage the patient on the waiting 
list.
Part 2 explores the post operative care 
of the LT recipient.
Further reading includes guidelines 
from BSG (1999),4 BASL (2012),5 EASL 
Guidelines for LT (2015)6 and acute liver 
failure (ALF)7 and AASLD guideline for 
LT (2013).8
Who to refer for Lt
Over 90% of LTs in the UK are performed 
for CLD, where a gradual destruction of 
liver tissue results in the familiar picture 
of jaundice, ascites, encephalopathy with 
coagulopathy and hypoalbuminaemia. 
A smaller number will have ALF3 7 and 
an even smaller number are transplanted 
for a non- failing liver, where there is 
survival advantage.9 This section iden-
tifies the reasons, which should prompt 
either a referral to an LTU or mandate 
an enquiry.
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Table 1 When referral/discussion with the LTU is required for a patient with ALF7
Paracetamol induced acute liver failure Non- paracetamol induced acute liver failure
 ► Arterial pH <7.30 or HCO3 <18
 ► INR >3.0 on day two or >4.0 thereafter
 ► Oliguria and/or AKI
 ► Altered level of consciousness
 ► Hypoglycaemia
 ► Elevated arterial lactate (>4 mmol/L) unresponsive to fluid 
resuscitation
 ► pH <7.30 or HCO3 <18mmol/l
 ► INR >1.8
 ► Oliguria/renal failure or Na <130 mmol/L
 ► Encephalopathy, hypoglycaemia or metabolic acidosis
 ► Bilirubin >300 umol/L (17.6 mg/dL)
AKI, acute kidney injury; ALF, acute liver failure; CLF, chronic liver failure; INR, international normalised ratio; LT, liver transplantation; LTU, liver transplant 
unit.
Box 1 Causes of chronic liver failure (CLF)
Causes of CLF:
 ► Alcohol.*
 ► Non- alcoholic fatty liver disease.
 ► Chronic viral hepatitis (B, C and D).
 ► Autoimmune liver disease (Primary Biliary Cholangitis, 
Primary Sclerosing Cholangitis, Autoimmune Hepatitis 
and overlap syndromes).
 ► Wilson’s disease.
 ► Genetic haemochromatosis.
 ► Alpha-1 antitrypsin deficiency.
 ► Secondary sclerosing cholangitis.
 ► Congenital hepatic fibrosis and other congenital or 
hereditary liver diseases.
*Alcoholic hepatitis tends to present acutely, frequently with no history of 
liver disease. Most patients recover with abstinence, but recent studies have 
demonstrated excellent outcomes with liver transplant in highly selected 
patients.44 45
Acute liver failure
While there are several ALF definitions,7 the critical 
elements for the purpose of this guideline, are the three 
cardinal features of encephalopathy, jaundice and coag-
ulopathy appearing in a patient who, less than 6 months 
ago, had no evidence of advanced liver disease. The chal-
lenge for the generalist in an AMU or emergency depart-
ment environment is establishing the diagnosis of severe 
liver injury quickly and minimising the delay in seeking 
help.10 Early discussions with LTU enable decisions on 
comorbidities or contraindications to LT (see below) to 
be addressed before hepatic encephalopathy develops 
and safe transfer becomes too high- risk.
Causes of ALF
Despite changes to packaging, paracetamol (aceta-
minophen) poisoning remains the the most common 
cause for ALF in the UK.11 The next most common 
cause is non- A- to- E hepatitis, then other drug induced 
liver injuries (prescribed, herbal and proscribed), viral 
hepatitis and ischaemic hepatitis. Malignancy (primary 
or secondary), pregnancy (AFLP/HELLP), vascular 
(including Budd- Chiari Syndrome) and metabolic disor-
ders are rarer causes.
Alcoholic hepatitis is considered in the CLD section, 
as is acute on chronic liver failure (AoCLF).
When to consider referral/discussion with the LTU in ALF
Once diagnosed, the ALF patient should be managed 
in an HDU environment and discussed with a LTU 
(see table 1). Important details include any history of 
paracetamol ingestion (timing, frequency, ‘staggered’), 
pregnancy, other drugs (prescribed, herbal or proscribed), 
comorbidity (mental and physical health), laboratory 
results (including PT, pH, arterial lactate, glucose, renal 
function, viral screen, autoantibodies and immunoglob-
ulins) and liver imaging. Ideally, patients are safer trans-
ferred before encephalopathy appears, although there is 
little published guidance covering this important issue.
Table 1 outlines clinical features in paracetamol and 
non- paracetamol ALF that correlate with poor outcome 
and mandate referral. Rarely, non- paracetamol ALF, can 
present with ascites, deep jaundice and even variceal 
haemorrhage, where the short history remains the only 
clue to ALF.
chronic liver failure
CLF occurs on the background of established liver 
cirrhosis. The typical clinical features include jaundice, 
ascites, encephalopathy, sarcopenia along with labo-
ratory features, such as hypoalbuminaemia and coag-
ulopathy, often associated with a rising creatinine and 
hyponatraemia as liver disease advances. Box 1 describes 
common causes of CLF.12
Acute on chronic liver failure
Acute- on- chronic liver failure (AoCLF) is a syndrome 
characterised by acute decompensation of CLD associ-
ated with organ failures and high short- term mortality. 
Sepsis, active alcoholism and relapse of chronic viral 
hepatitis are the most common reported precipitating 
factors, but still only account for perhaps half the cases, 
the remainder have no identifiable trigger. The poor 
prognosis mimics that seen in ALF and mandates an 
expedited triage and consideration for LT. However, 
while LT remains the definitive treatment, sadly very few 
prove suitable.13
When to consider referral/discussion with the Ltu in cLf 
or AocLf
Liver transplantation should be considered, when a 
patient with established liver disease develops any of 
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Figure 1 Clinical features of hepatic decompensation.
Table 2 Other aetiologies (non- liver failure) suitable for LT5 6 8 15
variant syndromes* Hepatocellular carcinoma (HCC)†
 ► Hepatopulmonary syndrome
 ► Persistent and intractable pruritus
 ► Polycystic liver disease
 ► Familial hyperlipidaemia
 ► Recurrent cholangitis
 ► Familial amyloidosis
 ► Hepatic epithelioid haemangioendothelioma
 ► Nodular regenerative hyperplasia
 ► Hereditary haemorrhagic Telangectasia
 ► Ornithine transcarbamylase deficiency
 ► Glycogen storage disease: symptomatic or presence
of hepatic adenoma(s)
 ► Primary hyperoxaluria: presence of renal impairment
 ► Porphyria
 ► Maple syrup urine disease
 ► Portopulmonary hypertension
Consider referral if raised mean pulmonary artery pressure 
(≥25 mm Hg),  PVR >120 dynes/s/cm−5: PCWP <15 mm Hg 
with clinical response to medical therapy
 ► Up to 25% of liver transplants in UK have HCC
 ► Associated with most CLD (HBV, HCV, ALD, NAFLD, autoimmune liver 
disease, haemochromatosis) and Aflatoxin ingestion
 ► Current LT selection criteria:
 – Single tumour <5 cm in diameter, or
 – Up to five tumours all ≤3 cm, or
 – Single tumour >5 cm and ≤7 cm in diameter if no progression over 6 
months (larger HCC’s can be ‘downstaged’ by local therapies and then 
considered for transplantation)
 – AFP <1000
*A variant syndrome is a patient with chronic liver disease whose UKELD score is <49.
†All patients with HCC should be managed within a Liver cancer MDT, which would be expected to recommend referral for liver transplantation as one of the potential 
‘outcomes’.
AFP, alpha foetoprotein; ALD, alcoholic liver disease; CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non alcoholic fatty liver disease; 
PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance.
the typical features of decompensation (figure 1). As 
decompensation correlates with rising morbidity and 
mortality, the supervising clinician should reflect on the 
key considerations outlined below.
Key considerations in patients with hepatic decompensation
1. Is the decompensation potentially reversible (for exam-
ple with abstinence in the case of ALD or with anti- virals 
in untreated chronic viral hepatitis)* or
2. If not reversible, is the patient suitable for LT*? or
3. Are there any contraindications to LT such as comorbidi-
ty which preclude transplant* (see table 5) or
4. If not currently suitable for transplant, could a patient 
become suitable with treatment or an intervention*?
*If in any doubt, seek advice from local LTU
Bear in mind that it is possible for a patient to be too 
unwell for LT if the referral is made too late.
To aid with the assessment of suitability for referral, 
the UK Model for End- Stage Liver Disease (UKELD) 
score can be calculated. The UKELD score is devised 
from patient’s INR, serum sodium, creatinine and 
bilirubin (https://www. odt. nhs. uk/ transplantation/ 
tools- policies- and- guidance/ calculators/).14 UKELD 
scores  ≥49  indicate  survival  advantage  for  LT  over 
conservative management in patients with irreversible 
decompensation.
Patients with decompensated CLD, unsuitable for 
LT, should have this conclusion documented and 
receive symptom- directed care.
non-liver failure indications for liver transplantation
Some patients will still benefit from LT, even though 
their liver is not failing (i.e, likely to cause death within 
12 months). This would include patients with cirrhosis 
and a UKELD score under 49, such as PBC patients 
with intractable pruritus (see table 2).5 6 8 15
hoW to refer for Lt
The next step is referral to the nearest LTU (see online 
supplementary appendix 1). For ALF patients, a tele-
phone referral is obligatory, but for all other indica-
tions, a written referral suffices. Email may speed the 
referral process, but correspondence with a named 
individual in LTU encourages collaborative dialogue 
between referring and transplant physicians. Most 
referrals for CLD patients come from secondary care 
hepatologists or gastroenterologists, but referrals are 
welcomed from any source in primary or secondary 
care.
What will the Ltu want to know?
The LTU will require details of the primary liver 
disease and its complications, comorbidity, compli-
ance issues, alcohol or drug misuse, family support, 
previous abdominal surgery and cancer.
A sample transplant assessment tool used is attached 
as online supplementary appendix 2, but shouldn’t 
replace a letter covering the above issues.
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Table 3 Local investigations and key information to include in referral letter (more details in online supplementary appendices 3–5)
Comorbidity
(include all details of pathologies, 
and important negatives)
investigations
(general investigations as below) Disease- specific investigations
Cardiovascular Chest X- ray PSC: colonoscopy and recent liver imaging
Respiratory ECG PBC/AIH: drug history
Renal Echocardiogram Hepatitis B: screening tests and viral load
Bone Oxygen Saturation Hepatitis C: details of treatment
HIV Analysis of Ascites HCC: recent imaging and MDT discussions
Obesity Endoscopy PLD/PLKD: brain imaging for Berry aneurysms
Surgical/anaesthetic history Nutritional assessment Budd- Chiari syndrome: history of shunts.
Nutrition Assessment of the performance status Wilson’s disease: details of treatments
Metabolic syndrome Up to date blood tests and UKELD Encephalopathy: brain imaging, ammonia, number connection tests
Non- hepatic cancer Adherence/addiction
Infectious disease   Ascites: number of drains, episodes of SBP
Social support   Alcohol related liver disease: period of abstinence, engagement with 
addiction services and so onDisabilities   
Alcohol and substance abuse     
Mental health     
Smoking     
AIH, Autoimmune Hepatitis; ArLD, Alcohol related Liver Disease; HCC, Hepatocellular Carcinoma; MDT, Multi Disciplinary Team; NG, Naso- gastric; NICE, 
National Institute for Health & Care Excellence; PBC, Primary Biliary Cholangitis; PLD/PLKD, Polycystic Liver Disease/Polycystic Liver & Kidney Disease; PSC, 
Primary Sclerosing Cholangitis; SBP, Spontaneous Bacterial Peritonitis; TC, Transplant Co- ordinator.
The quality and content of the referral can influ-
ence the pace of transplant assessment. This guide is 
not intended to be exhaustive, but ensures referrers 
provide critical information including; general inves-
tigations required prior to referral (online supplemen-
tary appendix 3); disease specific data required by 
LTU (online supplementary appendix 4) and comor-
bidities, psychosocial factors and addiction data that 
may inform the transplant assessment process (online 
supplementary appendix 5). All summarised in table 3.
considerations in patients with alcohol and drug-use 
disorders
Alcohol
Best practice suggests that patients benefit from early 
referral to, and engagement with, local addiction 
services. Repeated non- adherence with documented 
advice to abstain from alcohol is an absolute contrain-
dication to LT, so all discussions regarding the require-
ment for lifelong abstinence must be documented and 
the patient informed of the implication.
The UK Liver Advisory Group16 and National Insti-
tute for Health and Clinical Care Excellence (NICE)17 
have recently updated the policies relating to referral 
of alcohol related liver disease (ArLD) patients for 
consideration of LT.
Patients:
 ► Who are alcohol dependent and continue drinking (even 
at reduced levels) should not be referred. Referral to 
alcohol services and engagement is mandatory.
 ► Who, after 3 months of validated abstinence, still have 
an indication for liver transplant, should be referred. 
Validation of abstinence includes random blood alcohol 
levels, alcohol metabolite testing and support from 
addiction services.17
 ► Who are abstinent for <3 months, and positively 
engaged with addiction services, can be referred if there 
are issues (nutrition, frailty, etc) that might complicate 
the assessment, or death from liver disease may occur 
within 3 months.
Thus, there is no absolute rule governing the period 
of abstinence, other than patients must be abstinent at 
the time of referral. A pragmatic approach is to advise 
all patients with a failing liver due to alcohol, to become 
abstinent and engage with addiction services. If there is 
no immediate indication for referral for LT (as outlined 
in NICE guidance) then wait for 3 months to observe 
and if no improvement occurs, refer for LT. If, at 3 
months, there is evidence of ongoing liver recovery, 
then a further 3- month deferment may optimise liver 
recovery, and also test the patient’s commitment to 
abstinence. At 6 months of abstinence, little further 
recovery can be expected and referral for LT is appro-
priate for any patient who remains in liver failure.
Drug addiction/misuse
Drug testing is part of the assessment for such patients. 
The use of prescribed methadone or buprenorphine 
replacement therapy does not preclude assessment for 
LT. However, current use of non- prescribed controlled 
drugs, addictive medications or ‘designer’ alternatives 
precludes referral.
Lt Assessment
On receipt of a referral, the LTU determines whether 
the assessment requires urgent transfer, elective 
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Figure 2 Flow diagram displaying the process of LT assessment 
from initial referral through workup and listing meeting, to monitoring 
on the list and either transplant/ death or suspension from the list. 
The roles and responsibilities of the local unit and the TC are shown. 
LT, liver transplant; MDT, multi- disciplinary team; NG, naso- gastric; TC, 
transplant coordinator; UKELD, UK Model for End- Stage Liver Disease
Table 4 Absolute and relative contra- indications to LT
Absolute contraindications Relative contraindications*
Untreated HIV* Inadequate social support
Severe extrahepatic disease with 
predicted mortality >50% at 5 years 
including psychiatric disorder
Smoking
Severe irreversible pulmonary disease Certain anatomical variants
Ongoing alcohol misuse Extensive previous abdominal 
surgery
Active illicit drug use BMI >40 kg/m2
Certain anatomic variants Poor clinic attendance and/or 
adherence
Ongoing extra- hepatic sepsis*   
Active or previous extra- hepatic 
malignancy†
  
Liver cancer outside criteria*   
*These contra- indications can be temporary and require discussion with 
LTU.
†LT is considered for patients with neuroendocrine tumours (requires 
referral to national panel).46
BMI, body mass index; LT, liver transplant; LTU, liver transplant unit.
inpatient review, outpatient review or a combination 
approach. The referral- to- decision times of LTUs 
should be available for patients and referring hospitals 
(see figure 2).18
The aims of the liver transplant assessment are:
 ► To confirm the hepatological diagnosis.
 ► To confirm medical treatment has been optimised.
 ► To confirm that LT remains the most appropriate option.
 ► To evaluate mental and physical health comorbidities.
 ► To identify any contraindications.
 ► To ensure patients are fully informed of LT.
The transplant assessment is managed by the trans-
plant coordinator (TC) and performed by the core 
MDT, consisting of physician, surgeon, anaesthetist, 
social worker, TC and dietician with additional input 
from pharmacist, addiction specialist, renal physician, 
oncologist and psychiatrist (see online supplementary 
appendix 6).
transplant coordinator
The LT evaluation is supervised by the TC.19 The TC 
communicates directly with the patient and family/
support network. This relationship evolves over the 
assessment process and beyond, depending on progress 
(figure 2). The TC gains invaluable insight into the 
candidate.
As up to 40% of assessments are declined, the TC’s 
role includes advising and supporting such individuals, 
especially those who assumed referral automatically 
implied acceptance onto the waiting list. For patients 
accepted onto the waiting list, the TC communicates 
with patient’s referring hospital, GP and community 
services. The TC provides an explanation of what 
patients can expect while waiting and when called in 
for LT.
Indications for Lt
The transplant hepatologist confirms the primary liver 
condition (section 2), makes certain that medical treat-
ment has been optimised, and ensures disease specific 
investigations are completed (see online supplemen-
tary appendices 3-5).
contraindications to Lt
Table 4 describes absolute and relative contraindica-
tions to LT.
conclusion of transplant assessment
MDT decisions
Following assessment, candidates are discussed at the 
MDT meeting with three potential outcomes: decline, 
defer, or accept. For those declined, the option of a 
second opinion, from another transplanting centre, 
is discussed with the patient and carers either by the 
hepatologist or the TC. Responsibility for such a 
further referral rests with the patient’s local physician 
or GP.
Some patients require further optimisation such as 
nutritional or cardio- respiratory input, prior to acti-
vation on the waiting list. Such ‘deferred’ patients 
require re- discussion, once the additional elements are 
addressed.
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The remainder of assessments will be ‘accepted’ and 
placed on the LT waiting list. The option of live dona-
tion will be discussed, if appropriate.
consent for Lt
Consent for LT for candidates who retain mental 
capacity includes the general guidance for individuals 
undergoing any clinical intervention (see www. gmc- uk. 
org). However, the nature and risks of solid organ trans-
plantation, means the process is more complex. Fuller 
guidance is given by the British Transplantation Society 
and National Health Service Blood and Transplant 
(https:// bts. org. uk/ wpcontent/ uploads/ 2016/ 09/ 12_ 
BTS_ NHS_ Consent_ April_ 2013- 1. pdf). LTU’s provide 
oral and written information concerning the risks and 
benefits of LT for patients and their carers, incorporating 
outcomes, donor organ related risks (infective, malig-
nant, autoimmune, metabolic and others), procedure 
risks, disease recurrence and the need for adherence and 
life- long follow- up. The right to decline certain organs is 
carefully discussed (see Part 2, figure 1).
hoW to mAnAge the pAtIent on the 
WAItIng LIst
Waiting list
During 2015–2016, 1161 patients joined the LT 
waiting list in the UK. At 1- year post- registration, 73% 
of patients had received a LT, 9% had died waiting or 
been removed due to deterioration. A further 4% were 
removed for other reasons such as clinical improve-
ment, non- compliance or at patient’s request. The 
remaining 14% were still waiting.3
The waiting times depend on several factors, 
including recipient blood group, size and illness 
severity (i.e. UKELD score). The median waiting time 
is currently 135 days, though this is shorter for recip-
ients who are blood group AB (56 days), A (84 days) 
and B (129 days) than blood group O (256 days).3 
Details of organ allocation are outlined in Part 2.
monitoring on the waiting list
Patients listed for LT must be monitored closely for 
changes in their clinical circumstances. The ‘local’ team 
manage all the patient’s routine care, but as this may 
impact on their suitability for LT, regular and careful 
communication with the LTU, via the TC is essential 
(see figure 2).
optimisation of patients on the waiting list
Managing deterioration
Patients on the LT waiting list frequently present 
with decompensation to their referring hospital. This 
decompensation carries a significant mortality risk.20
The Lancet Standing Commission on Liver Disease 
has highlighted the need to focus on improving the care 
for acutely ill, hospitalised patients with liver disease.21 
Ideally, hospitals should have in place a ‘care bundle’ 
for patients admitted with decompensated cirrhosis.22
Management of listed patients in the referring hospital
Patients on LT waiting list require monthly review 
in gastroenterology/hepatology outpatient clinics for 
nutritional review, blood- sampling, UKELD calcu-
lation and surveillance tests for cirrhosis. The LTU 
should be appraised of any deterioration, as listing 
status may need reviewing. Transfer to the LTU for 
acute deterioration is sometimes necessary, but if not, 
the confidence of patients and their carers is enhanced 
when there is open dialogue between the local hospital 
and the LTU.
Nutrition
Most patients with end- stage cirrhosis are malnour-
ished23 and malnutrition in recipients predicts poorer 
outcome after LT.24 25 LTUs recommend a nutritional 
supplement for patients on the waiting list for the bene-
ficial effect on anthropomorphic indices.26 Obesity is 
increasingly common among patients on the waiting 
list for LT. Sarcopenic obesity, or severe muscle deple-
tion in the setting of obesity, is reported in almost half 
of obese patients with cirrhosis and is associated with 
an increased risk of pre- LT mortality. For patients with 
compensated cirrhosis, traditional lifestyle modifica-
tions are safe, but very low calorie diets (<1000 calo-
ries/day) are not safe. For decompensated cirrhotics, 
low- calorie diets may exacerbate sarcopenia and 
malnutrition, so such patients should maintain caloric 
intake with higher protein, nutrient- rich foods.27
Exercise
There is little data on exercise in patients waiting for 
LT. However, exercise programmes known as ‘preha-
bilitation’ can improve functional capacity and post-
operative outcomes in patients with liver disease 
awaiting major surgery.28 Recently, the Birmingham 
group published a proposal to clarify this issue in 
patients awaiting LT.29 Most centres advise a sustained 
exercise target of up to 25 minutes daily, depending on 
the individual patients pre- existing activity levels and 
physical impairments. A step- counter (available as an 
app) is helpful for target setting and the Birmingham 
team’s proposal also incorporates specific advice on 
functional resistance exercise training that can readily 
be carried out at home.29
Other lifestyle factors
Lifestyle factors are central to survival both on the 
waiting list and beyond. Patients should be supported 
to make positive and sustainable lifestyle behaviour 
changes.
Active engagement with alcohol services is key for 
any ArLD patient and this may be a condition for 
listing. Alcohol use rates of 15%–25% have been 
reported for patients on LT waiting lists so ongoing 
monitoring (blood, urine, breath or hair) and support 
are essential.30 Most centres require random testing 
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Key points
 ► Consider all patients with decompensated CLD for liver 
transplantation
 ► Discuss all ALF patients with LTU
 ► Provide LTU with details of primary liver disease and co- 
morbidities in mental & physical health
 ► Patients on transplant waiting list are the shared 
responsibility of referrer and LTU
 ► The palliative care needs of the patient are a critical part 
of the transplant assessment process.
for patients listed for ArLD and will liaise with the 
local hospital to facilitate timing and frequency.
Active smoking increases all- cause mortality at 5 
and 10 years after LT31 due to additional surgical 
complications, more cardiovascular disease, sepsis 
and solid- organ malignancy.31–34 Smokers must 
engage in a smoking cessation programme and if 
smoking cessation is a condition for listing, patients 
should expect carbon monoxide breath- testing.
Psychosocial support
Patients listed for LT have high rates of psychological 
distress and depression which reduces quality of life, 
adaptive coping and functional status.35 Significant 
depression reduces pretransplant survival.36 Waiting 
times, concern about deterioration, organ scar-
city and false- alarms contribute to patient anxiety. 
All patients require screening for depression and 
management accordingly.
Patients and carers receive education, including 
attendance at patient information sessions at the 
time of listing. This should include access to ‘expert 
patients’, information on LT services, the patient 
pathway, support groups and services offering 
psychological, social and spiritual/cultural support. 
The LTU have a transplant healthcare professional 
available 24/7 for telephone advice for patients and 
carers and ongoing contact with TC, specialist nurses 
and a social worker, as necessary.
pALLIAtIve cAre And Lt
Liver transplantation is the gold standard treatment 
for many patients with ALF, CLF and liver cancer, 
however, almost half of those assessed are declined 
and 20% patients die while waiting, meaning four 
people die for every one transplanted. Patients with 
CLD have a variable level of access to palliative care 
services, which can vary in quality.37 38
By definition, those listed for LT have advanced 
disease and therefore, concomitant physical and 
psychosocial issues. Patients suffer from a high 
physical symptom burden39 40; symptoms are often 
complex and dramatic, frequently necessitating 
hospital admission41 with a poor evidence base to 
support the use of many drugs. Patients also suffer 
complex psychosocial issues including the stigma of 
liver disease, complex socioeconomic background 
circumstances and uncertainty associated with the 
potential for re- compensation and the possibility of 
transplantation.
Maintaining hope while ensuring an appropriate 
holistic assessment of the patient’s needs is chal-
lenging for everyone involved in delivering care. 
Discussions on end- of- life care including prefer-
ences, is an essential component in the management 
of patients with advanced liver disease, including 
those awaiting LT.
Early palliative care intervention can improve 
quality of life by improving symptom burden and 
mood, alongside less aggressive treatment and a 
reduction in hospitalisation.42 43 An assessment of 
palliative care needs should form an integral part 
of any transplant assessment process. Collaborative 
working is essential at a time of such great uncer-
tainty if the overall quality of life for these patients 
and their carers is to be improved.
concLusIons
 ► All patients with decompensated CLD, should be consid-
ered for LT.
 ► All ALF patients should be discussed with the LTU and 
transferred in timely fashion, if appropriate.
 ► LT may be considered for variant syndromes, HCC and 
various other non- liver failure indications after discus-
sion with LT team.
 ► The LTU require details of diagnosis, comorbidity, nutri-
tional status and frailty in order to complete evaluation.
 ► Patients on the LT waiting list are shared between the 
referring centre and LTU. Good communication between 
the various healthcare professionals is critical. For 
patients who deteriorate, candid discussions with indi-
viduals and their relatives coupled with timely utilisation 
of palliative care services should optimise outcome for 
all concerned.
Author affiliations
1Department of Hepatology, York Teaching Hospitals NHS Foundation Trust, 
York, UK
2Pharmacy department, King’s College Hospital NHS Foundation Trust, London, 
UK
3South West Liver Unit, Plymouth Hospitals NHS Trust, Plymouth, UK
4Liver Unit, University Hospitals Birmingham NHS Foundation Trust, 
Birmingham, UK
5Department of Cellular Pathology, University of Birmingham, Birmingham, UK
6Department of Hepatology, York Teaching Hospitals NHS Foundation Trust, 
York, UK
7Liver Transplantation Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK
8Department of Hepatology, Cambridge University Hospitals NHS Foundation 
Trust, Cambridge, UK
9Liver Unit, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, 
Newcastle upon Tyne, UK
10Liver Transplantation & HPB Surgery, King’s College Hospital NHS Foundation 
Trust, London, UK
11Liver Transplantation & HPB surgery, University Hospitals Birmingham NHS 
Foundation Trust, Birmingham, UK
12Liver Unit, University Hospitals Birmingham NHS Foundation Trust, 
Birmingham, UK
 o
n
 M
arch 30, 2020 by guest. Protected by copyright.
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101215 on 25 February 2020. Downloaded from
 
Millson C, et al. Frontline Gastroenterology 2020;0:1–10. doi:10.1136/flgastro-2019-1012158
LivER
13Liver Transplantation & HPB Surgery, Leeds Teaching Hospitals NHS Trust, 
Leeds, UK
14Pharmacy department, York Teaching Hospitals NHS Foundation Trust, York, 
UK
15Palliative Care Medicine, King’s College Hospital NHS Foundation Trust, 
London, UK
16Liver Transplantation Service, Royal Free London NHS Foundation Trust, 
London, UK
17Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK
18Department of Hepatology, Royal Free London NHS Foundation Trust, London, 
UK
19Department of Hepatology, Royal Free London NHS Foundation Trust, London, 
UK
20Liver Unit, University Hospitals Birmingham NHS Foundation Trust, 
Birmingham, UK
Acknowledgements Two individuals, Ms Lorna Tong and Mrs 
Elizabeth Crawshaw, read the manuscripts and offered critique 
as ‘expert patients’ and the authors are grateful for their critical 
input. The authors are thankful to Ms Robyn Southeran from 
the Medical Illustration department at York Hospital NHS FT.
Contributors There were 20 authors involved in the production 
of these two articles concerning liver transplantation. The 
original project was divided into an introduction, nine 
sections and a conclusion. From that original outline, the 
sections were written by writing groups and then collated. 
The nine sections were then divided into two halves for the 
purposes of publication, after discussion with the editor of 
FG. Each contributor provided editing input, to the project, 
as the manuscript went through its many iterations. The 
specific contribution/participation of each contributor are 
as follows: CM (consultant hepatologist in a DGH): senior 
author. Initiated section divisions, collected manuscripts. 
Contributed to writing by adding DGH aspects to all part 1 
and management of post- transplant patient section. Edited all 
tables and oversaw the process. CM is responsible for overall 
content as guarantor. A Considine is a consultant pharmacist. 
She co- wrote the section on the Immunosuppression agents 
in Part 2 with Prof Neuberger and gave input into Part 1 
particularly with the ‘disease specific considerations’ and where 
medication interactions can occur. MC (consultant transplant 
hepatologist): Co- authored the section on 'Management 
of the patient on the waiting list' and then read both Part 
1 and 2 of final submission as an additional critique for all 
sections. Critical role in planning and acquisition of data for 
inclusion into guideline, along with evaluation of relevance 
to project. Final manuscript editing and approval. AH 
(consultant transplant hepatologist): Co- authored the section 
on 'How to refer', and then drew up the tables and added 
valuable additional input, as well as re- write participation for 
the sections, when the original submission was too lengthy. 
Critical role in planning, final manuscript editing and approval. 
SH is a consultant histopathologist and wrote the section 
on cellular rejection in Part 2. He added valuable oversight 
in Part 1, particularly as both parts were too lengthy and 
required significant reduction in word count. JH (consultant 
hepatologist in a DGH) wrote the section on Transplant 
assessment and with KJ refined this section, to focus on the 
DGH referrer. JH also read both completed parts to provide 
the DGH perspective on these elements of liver transplantation 
and ensure focus was correct for that audience. Critical role 
in planning and acquisition of data for inclusion into Part 1 of 
guideline, along with evaluation of relevance to project. Part 
1 and 2 final manuscript editing and approval. KJ (Transplant 
co- ordinator) provided section on the Transplant co- ordinator 
and then gave critical input for aspects on process of organ 
selection along with RP (below). Critical role in planning and 
acquisition of data for inclusion into guideline, along with 
evaluation of relevance to project. Final manuscript editing 
and approval JL (consultant transplant hepatologist) co- 
authored the section on 'How to refer' and provided editorial 
input for part 2. Critical role in planning and acquisition of 
data for inclusion into guideline, along with evaluation of 
relevance to project. Final manuscript editing and approval SM 
(consultant transplant hepatologist) co- authored the section 
on 'How to manage the patient on the waiting list' bringing 
together the co- ordinators input with the transplant centre 
and the interaction with secondary care referring centre. 
Providing insights from both sides of the secondary/tertiary 
care interaction and then editing the initial contribution of 
the section to a more manageable section. Ensuring relevance 
of data collected for the project along with final manuscript 
editing and approval KM (consultant transplant surgeon) 
contributed to the section in part 2 on Transplant surgery and 
outcomes. KM also provided input in Part 1 into section on 
Transplant assessment and previous surgery. Critical role in 
planning and acquisition of data for inclusion into guideline, 
along with evaluation of relevance to project. Final manuscript 
editing and approval DM (consultant transplant surgeon) 
co- authored the section on Transplant surgery with KM and 
post- transplant surgical complications. He also provided input 
in Part 1 into section on Transplant assessment and previous 
surgery. Critical role in planning and acquisition of data for 
inclusion into guideline, along with evaluation of relevance to 
project. Final manuscript editing and approval JN (consultant 
transplant hepatologist) wrote the section on Post- Transplant 
Immunosuppression with the aid of A Considine. Prof 
Neuberger also contributed to the Part 1 in editorial role, when 
he helped with the original concept, he provided a critical role 
following the original guideline production and prior to it’s 
splitting into two halves (Part 1 and 2) and ensuring correct 
focus was maintained when the manuscript was reduced in 
size. RP (consultant transplant surgeon) wrote the section on 
organ allocation and donation. He also made a significant 
contribution to the post- operative care and complications 
sections and the pre- op evaluation (Part 1). Critical role in 
planning and acquisition of data for inclusion into guideline, 
along with evaluation of relevance to project. Final manuscript 
editing and approval AP (Liver Pharmacist) contributed to 
Part 2 immunosuppression section, but also gave useful input 
into Part 1 and 2 from point of view of medication and drug 
interactions, particularly with viral hepatitis treatment. Critical 
role in evaluating data for inclusion into guideline, along 
with maintain relevance to project. Final manuscript editing 
and approval WP (Consultant in Palliative Care) authored 
the section on Palliative Care and Transplantation in Part 1. 
Her contribution in Part 2 was proof- reading and providing 
critical input. Critical role in planning and acquisition of 
data for inclusion into guideline, along with evaluation of 
relevance to project. Final manuscript editing and approval LS 
is a Transplant co- ordinator. She contributed to the section on 
How to refer a patient for liver transplant (Part 1) and gave 
input into section on Organ allocation (Part 2). Critical role in 
planning and acquisition of data for inclusion into guideline, 
along with evaluation of relevance to project. Final manuscript 
editing and approval KS (consultant transplant hepatologist) 
wrote the section on 'When to refer' in Part 1, but also gave 
significant editorial input to entire project, at the time of 
the section merge and subsequent division into two halves. 
Critical role in planning and acquisition of data for inclusion 
into guideline, along with evaluation of relevance to project. 
Final manuscript editing and approval DT and RW (consultant 
transplant hepatologists) co- authored the section on Transplant 
outcomes. They provided critical input into Part 1 as well, 
with respect to referral process. Critical role in planning and 
acquisition of data for inclusion into guideline, along with 
evaluation of relevance to project. Final manuscript editing and 
approval. DT (consultant transplant hepatologist) co- authored 
the section on Postoperative care and complications (non- 
surgical). DT also supported the entire process by helping 
the lead author with editing sections and discussion of tables, 
pictures, deciding on section inclusion, data relevance and final 
manuscript editing and approval.
Funding The authors have not declared a specific grant for this 
research from any funding agency in the public, commercial or 
not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally 
peer reviewed.
 o
n
 M
arch 30, 2020 by guest. Protected by copyright.
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101215 on 25 February 2020. Downloaded from
 
Millson C, et al. Frontline Gastroenterology 2020;0:1–10. doi:10.1136/flgastro-2019-101215  9
LivER
Open access This is an open access article distributed in 
accordance with the Creative Commons Attribution Non 
Commercial (CC BY- NC 4.0) license, which permits others 
to distribute, remix, adapt, build upon this work non- 
commercially, and license their derivative works on different 
terms, provided the original work is properly cited, appropriate 
credit is given, any changes made indicated, and the use is non- 
commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 
0/.
ORCiD iD
Charles Millson http:// orcid. org/ 0000- 0001- 6989- 9497
ReFeRenCes
 1 Calne RY. Transplantation of the liver. Ann Surg 
1978;188:129–38.
 2 Neuberger J. Liver transplantation in the United Kingdom. 
Liver Transpl 2016;22:1129–35.
 3 NHS Blood and Transplant. Annual report on liver 
transplantation 2015/2016.
 4 Devlin J, O'Grady J. Indications for referral and assessment 
in adultliver transplantation: a clinical guideline. Gut 
1999;45:vi1–22.
 5 BASL. Guidelines on referral for liver transplant assessment, 
2012. Available: http:// odt. nhs. uk/ pdf/ advisory_ group_ papers/ 
LAG/ referral_ for_ transplantation. pdf
 6 European Association for the Study of the Liver. Electronic 
address:  easloffice@ easloffice. eu. EASL clinical practice 
guidelines: liver transplantation. J Hepatol 2016;64:433–85.
 7 Wendon, J, Cordoba J, Dhawan A, et al. EASL clinical practical 
guidelines on the management of acute (fulminant) liver 
failure. J Hepatol 2017;66:1047–81.
 8 Martin P, DiMartini A, Feng S, et al. Evaluation for liver 
transplantation in adults: 2013 practice guideline by the 
American association for the study of liver diseases and 
the American Society of transplantation. Hepatology 
2014;59:1144–65.
 9 European liver transplant registry. Available: http://www. eltr. 
org
 10 Khan R, Koppe S. Modern management of acute liver failure. 
Gastroenterol Clin North Am 2018;47:313–26.
 11 Blackmore L, Bernal W. Acute liver failure. Clin Med 
2015;15:468–72.
 12 EASL practice guidelines for the management of patient with 
decompensated cirrhosis. Journal of Hepatology. In Press.
 13 Jalan R, Moreau R, Kamath PS, et al. Acute- On- Chronic liver 
failure: a distinct clinical condition. Seminars in Liver Disease 
2016;36:107–8.
 14 UKELD. Calculator. Available: https:// nhsbtdbe. blob. core. 
windows. net/ umbraco-assets-corp/./ ukeld_ calculator- 2. xls
 15 Sapisochin G, Bruix J. Liver transplantation for hepatocellular 
carcinoma: outcomes and novel surgical approaches. Nat Rev 
Gastroenterol Hepatol 2017;14:203–17.
 16 . Available: http:// odt. nhs. uk/ pdf/ liver_ selection_ policy. pdf
 17 Clinical guideline [CG115]. Nice guidance: Alcohol- use 
disorders: diagnosis, assessment and management of harmful 
drinking and alcohol dependence. Available: http://www. nice. 
org. uk/ guidance/ cg115
 18 Mathur AK, Talwalkar J. Quality measurement and 
improvement in liver transplantation. J Hepatol 
2018;68:1300–10.
 19 . Available: https://www. odt. nhs. uk/ odt- structures- and- 
standards/ organ- donation- retrieval- and- transplantation- teams/ 
role- of- transplant- recipient- co- ordinator/
 20 Moreau R, Jalan R, Gines P, et al. CANONIC study 
Investigators of the EASL–CLIF Consortium. acute- on- chronic 
liver failure is a distinct syndrome that develops in patients 
with acute decompensation of cirrhosis. Gastroenterology 
2013;144:1426–3.
 21 Williams R, Aspinall R, Bellis M, et al. Addressing liver disease 
in the UK: a blueprint for attaining excellence in health care 
and reducing premature mortality from lifestyle issues of excess 
consumption of alcohol, obesity, and viral hepatitis. Lancet 
2014;384:1953–97.
 22 McPherson S, Dyson J, Austin A, et al. Response to the 
NCEPOD report: development of a care bundle for patients 
admitted with decompensated cirrhosis—the first 24 h. 
Frontline Gastroenterol 2016;7:16–23.
 23 O'Brien A, Williams R. Nutrition in end- stage liver disease: 
principles and practice. Gastroenterology 2008;134:1729–40.
 24 Merli M, Giusto M, Gentili F, et al. Nutritional status: 
its influence on the outcome of patients undergoing liver 
transplantation. Liver Int 2010;30:208–14.
 25 Le Cornu KA, McKiernan FJ, Kapadia SA, et al. A prospective 
randomized study of preoperative nutritional supplementation 
in patients awaiting elective orthotopic liver transplantation. 
Transplantation 2000;69:1364–9.
 26 Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: 
exploiting a period of anabolic opportunity in cirrhosis. J 
Gastroenterol Hepatol 2012;27:430–41.
 27 Spengler EK, O'Leary JG, Te HS, et al. Liver transplantation in 
the obese cirrhotic patient. Transplantation 2017;101:2288–
96.
 28 Dunne DFJ, Jack S, Jones RP, et al. Randomized clinical trial of 
prehabilitation before planned liver resection. British Journal of 
Surgery 2016;103:504–12.
 29  Williams FR, Vallance A, Faulkner T. Home- Based 
exercise therapy in patients awaiting liver transplantation: 
protocol for an observational feasibility trial. BMJ Open 
2018;8:e019298.
 30 Erim Y, Böttcher M, Dahmen U, et al. Urinary ethyl 
glucuronide testing detects alcohol consumption in alcoholic 
liver disease patients awaiting liver transplantation. Liver 
Transplantation 2007;13:757–61.
 31 Leithead JA, Ferguson JW, Hayes PC. Smoking- Related 
morbidity and mortality following liver transplantation. Liver 
Transplantation 2008;14:1159–64.
 32 Herrero JI, Pardo F, D'Avola D, et al. Risk factors of lung, head 
and neck, esophageal, and kidney and urinary tract carcinomas 
after liver transplantation: the effect of smoking withdrawal. 
Liver Transplantation 2011;17:402–8.
 33 Pungpapong S, Manzarbeitia C, Ortiz J. Cigarette smoking 
is associated with an increased incidence of vascular 
complications after liver transplantation. Liver Transplantation 
2002;8:582–7.
 34 Mathur AK, Ranney DN, Patel SP, et al. The effect of smoking 
on biliary complications following liver transplantation. 
Transplant International 2011;24:58–66.
 35 De Bona M, Ponton P, Ermani M, et al. The impact of liver 
disease and medical complications on quality of life and 
psychological distress before and after liver transplantation. J 
Hepatol 2000;33:609–15.
 36 DiMartini A, Amanda Dew M, Javed L, et al. Pretransplant 
psychiatric and medical comorbidity of alcoholic liver disease 
patients who received liver transplant. Psychosomatics 
2004;45:517–23.
 37 NHS Liver Care. Nhs atlas of variation in healthcare for people 
with liver disease. London, 2013.
 38 NCEPOD report. Alcohol related liver disease: measuring the 
units, 2013.
 39 Boyd K, Kimbell B, Murray S, et al. Living and dying well with 
end- stage liver disease: time for palliative care? Hepatology 
2012;55:1650–1.
 40 Hope AA, Morrison RS. Integrating palliative care with 
chronic liver disease care. J Palliat Care 2011;27:20–7.
 41  Volk ML, Tocco RS, Bazick J, et al. Hospital readmissions 
among patients with decompensated cirrhosis. American 
Journal of Gastroenterology 2012;107:247–52.
 o
n
 M
arch 30, 2020 by guest. Protected by copyright.
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101215 on 25 February 2020. Downloaded from
 
Millson C, et al. Frontline Gastroenterology 2020;0:1–10. doi:10.1136/flgastro-2019-10121510
LivER
 42 Baumann AJ, Wheeler DS, James M, et al. Benefit of early 
palliative care intervention in end- stage liver disease patients 
awaiting liver transplantation. J Pain Symptom Manage 
2015;50:882–6.
 43 Walling AM, Asch SM, Lorenz KA, et al. Impact of 
consideration of transplantation on end- of- life care for 
patients during a terminal hospitalization. Transplantation 
Journal 2013;95:641–6.
 44 Thursz M, Morgan TR. Treatment of severe alcoholic hepatitis. 
Gastroenterology 2016;150:1823–34.
 45 Lee BP, Mehta N, Platt L, et al. Outcomes of early liver 
transplantation for patients with severe alcoholic hepatitis. 
Gastroenterology 2018;155:422–30.
 46 Moris D, Tsilimigras DI, Ntanasis- Stathopoulos I, et al. 
Liver transplantation in patients with liver metastases 
from neuroendocrine tumors: A systematic review. Surgery 
2017;162:525–36.
 o
n
 M
arch 30, 2020 by guest. Protected by copyright.
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101215 on 25 February 2020. Downloaded from
 
